TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05750017

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Low Dose Recombinant Herpes Zoster Vaccine (LZ901)
Description: 0.5 mL per dose, containing a total of 50 µg recombinant herpes zoster virus glycoprotein E, adjuvanted with alumina adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Dose Recombinant Herpes Zoster Vaccine (LZ901)
Description: 0.5 mL per dose, containing a total of 100 µg recombinant herpes zoster virus glycoprotein E, adjuvanted with alumina adjuvant.
Study: NCT06777212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training Program
Description: The Mindfulness Training Program is a 30-day behavioral intervention designed to help children with body-focused repetitive behaviors (BFRBs) such as nail-biting, skin-picking, and hair-pulling. Delivered through JD Health, the program includes daily audio-guided exercises focused on mindfulness techniques such as deep breathing, body scans, and emotional awareness. Children will be encouraged to practice mindfulness for 10-15 minutes each day, with the goal of improving emotional regulation, reducing impulsive behavior, and enhancing self-awareness. Family support is involved, with parents helping children track their progress and offering reinforcement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Education Program
Description: The Psychosocial Education Program is a 30-day behavioral intervention designed for children with body-focused repetitive behaviors (BFRBs), including nail-biting, skin-picking, and hair-pulling. Delivered through JD Health, the program provides daily educational content in the form of articles and coping strategies. The intervention focuses on improving emotional regulation, promoting family support, and developing positive behavioral strategies. Parents play an active role by reviewing the content with their children and helping them apply the strategies in daily life. Behavioral and psychological assessments are conducted at baseline, one month, and three months to evaluate the program's impact.
Study: NCT06775769

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Description: Laparoscopic ethanol sclerotherapy of endometrioma
Study: NCT05750017

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: High Dose Recombinant Herpes Zoster Vaccine (LZ901)
Description: 0.5 mL per dose, containing a total of 100 µg recombinant herpes zoster virus glycoprotein E, adjuvanted with alumina adjuvant.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL per dose, containing 4.5 mg sodium chloride.
Study: NCT05863988

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional Electrical Stimulation
Description: The group A will receive functional electrical stimulation 30-45 min session 5 days per week for 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upper Limb Loading Exercises
Description: The group B will receive Upper Limb Loading Exercises 30-45 min session 5 days per week for 8 weeks.
Study: NCT06527092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: VR is an interactive, multidimensional, computer-simulated environment accessed through a head-mounted device that blocks the view of the real world. This environment is projected in front of the user's eyes through sophisticated head-mounted displays, including a wide field of view and motion tracking systems

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bubbles
Description: A colorful light bubble gun was used for bubble therapy, which is one of the distraction methods.
Study: NCT06775769

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Routine Care
Description: Routine surgical management of endometrioma
Study: NCT06776614

Intervention type: PROCEDURE
Intervention: Decompressive Craniectomy
Description: The DC will be performed through a standard trauma incision, a retro-auricular C-shape or a Kempe incision and execute a 15x15 cm craniotomy with a C-shape durotomy. Dural closure will be at the discretion of the surgeon and the availability of resources, including duroplasty with aponeurotic galea, a suturable dural patch, a non-suturable dural patch, or simply a superficial dural cover with hemostatic materials like Surgicel® or Gelfoam®. There are multiple techniques for DC. The elected technique will be at the discretion of the treating neurosurgeon, but only front-parietal-temporal DC will be considered. The removed bone flap may be stored in an abdominal pouch in the right or left upper abdominal quadrants or by freezing in a bone or blood bank freezer.

Intervention type: PROCEDURE
Intervention: Expansion Craniotomy
Description: The EC will be performed through a retro-auricular C-shape incision and executing a 15x15 cm craniotomy with a C-shape durotomy. Dural closure will be at the discretion of the surgeon and the availability of resources, including duroplasty with aponeurotic galea, a suturable dural patch, a non-suturable dural patch, or simply a superficial dural cover with hemostatic materials like Surgicel® or Gelfoam®. The expansion craniotomy will be finished with a cranioplasty using a full set of 3-5 Rialto plates for bone graft closure. The selected technique will be at the discretion of the treating neurosurgeon, but only front-parietal-temporal EC will be considered.
Study: NCT06776939

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen therapy
Description: All patients are subject to both oxygen therapy groups in this randomized cross-over study. Study measurements are performed during several different disconnection sessions. Disconnection sessions can either be short (\<90 min) or long (12 hours). Both short and long disconnection sessions are performed twice; once with conventional oxygen, and once with high-flow tracheal oxygen as respiratory support.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen therapy
Description: All patients are subject to both oxygen therapy groups in this randomized cross-over study. Study measurements are performed during several different disconnection sessions. Disconnection sessions can either be short (\<90 min) or long (12 hours). Both short and long disconnection sessions are performed twice; once with conventional oxygen, and once with high-flow tracheal oxygen as respiratory support.
Study: NCT06777381

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single visit root canal treatment using ProTaper Universal rotary system
Description: single visit endodontic treatment will be performed using ProTaper Universal rotary system for root canal preparation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single visit root canal treatment using M-Pro rotary system
Description: single visit endodontic treatment will be performed using MPro rotary systems for root canal preparation.
Study: NCT06775795

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oat milk
Description: Participants will consume one portion of plant-based milk alternative (oat) which will provide approximately 200 µg of iodine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soya milk
Description: Participants will consume one portion of plant-based milk alternative (soya) which will provide approximately 200 µg of iodine

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cow's milk
Description: Participants will consume one portion of semi-skimmed cow's milk which will provide approximately 200 µg of iodine
Study: NCT05862467

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy (WET) via telehealth
Description: Written Exposure Therapy (WET) via telehealth
Study: NCT05691517

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study: NCT04723446

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No rinsing
Description: No rinsing
Study: NCT06261307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: Group intervention focusing on musical activities

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Circus intervention
Description: Group intervention focusing on acrobatics and circus activities
Study: NCT05691517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pH Low Insertion Peptide-exatecan Conjugate CBX-12
Description: Given IV
Study: NCT05372640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BET Bromodomain Inhibitor ZEN-3694
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging
Description: Undergo imaging evaluation
Study: NCT05427799

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Honey
Description: A mixed flora honey that will be obtained from local producers. and will be consumed by a daily dose of 0.5 g/kg body weight of honey by each participant and will be divided into two doses.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Other carbohydrate alternatives such as jell-o
Description: A daily dose of 0.5 g/kg body weight of Jell-O will be consumed by each participant and will be divided into two doses. Jell-O was selected as a source of sucrose with negligible phenolic capacity.
Study: NCT05274425

Intervention type: OTHER
Intervention: Enerzair 150/50/80 μg
Description: There is no treatment allocation. Patients administered Enerzair by prescription that have started before inclusion of the patient into the study will be enrolled.

Intervention type: OTHER
Intervention: Enerzair 150/50/160 μg
Description: There is no treatment allocation. Patients administered Enerzair by prescription that have started before inclusion of the patient into the study will be enrolled.
Study: NCT05826392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adolescent/Young Adult Self-Administered Web-Based Single-Session Intervention
Description: Web-Based, 30-minute self-administered intervention for adolescents
Study: NCT05750017

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL per dose, containing 4.5 mg sodium chloride.
Study: NCT05580302

Intervention type: OTHER
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: An anatomical T1 magnetic resonance image (MRI) with high resolution will be acquired on a separate day before the TMS experiment. The image will be imported into the neuronavigation system (Nexstim, Helsinki, Finland) to guide the localization of the primary motor cortex (M1) for laryngeal muscle representation. Prior to M1 mapping for laryngeal muscle representation, mapping of the representation for hand muscle representation will be performed. Hand region excitability (abductor pollicis brevis, APB) will be evaluated by using surface electrodes attached to the right-hand APB muscle. The cSP threshold is defined as the lowest TMS intensity that elicits a cSP in 5 out of 10 consecutive trials. Single-pulse cortical stimulations will be performed during the vocalization of sustained /i/ sound.

Intervention type: OTHER
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: An anatomical T1 magnetic resonance image (MRI) with high resolution will be acquired on a separate day before the TMS experiment. The image will be imported into the neuronavigation system (Nexstim, Helsinki, Finland) to guide the localization of the primary motor cortex (M1) for laryngeal muscle representation. Prior to M1 mapping for laryngeal muscle representation, mapping of the representation for hand muscle representation will be performed. Hand region excitability (abductor pollicis brevis, APB) will be evaluated by using surface electrodes attached to the right-hand APB muscle. The cSP threshold is defined as the lowest TMS intensity that elicits a cSP in 5 out of 10 consecutive trials. Single-pulse cortical stimulations will be performed during the vocalization of sustained /i/ sound.
Study: NCT06423794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHV-7000
Description: BHV-7000 75 mg taken once daily
Study: NCT06156930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group lavender oil
Description: The group will receive aromatherapy massage with a 5% mixture prepared with sesame oil and lavender oil for 10 minutes on both lower leg areas, three times a week for four weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group sesame oil
Description: The group will receive a massage with sesame oil on both lower leg areas for 10 minutes on each leg, three times a week for four weeks.
Study: NCT06402318

Intervention type: DEVICE
Intervention: A&M Breathalyzer PROTECT Kiosk
Description: The A\&M Breathalyzer PROTECT Kiosk will collect the mass spectrum breath readings from each participant, scan speed, and will autoanalyze noise and scan thresholds and sensitivity data.

Intervention type: DEVICE
Intervention: A&M Breathalyzer PROTECT Kiosk
Description: The A\&M Breathalyzer PROTECT Kiosk will collect the mass spectrum breath readings from each participant, scan speed, and will autoanalyze noise and scan thresholds and sensitivity data.
Study: NCT05443490

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic mixture with three bacterial strains with maltodextrin as a carrier.
Description: Sachets containing a probiotic mixture at concentrations equal to or greater than 1x10\^9 colony forming unit (CFU) per dose, with maltodextrin as excipient.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator with maltodextrin as a carrier.
Description: Sachets containing maltodextrin
Study: NCT06531291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: 250 mg, po, qd, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: 200 mg, iv, d1, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard chemotherapy
Description: Decided by PI
Study: NCT00571740

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study: NCT04857658

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: extraction orthodontic treatment plan
Description: patients will be referred for extraction of the upper and lower first premolars then orthodontic treatment will follow.
Study: NCT05902884

Intervention type: DEVICE
Group type: OTHER
Intervention: MSOT Acuity Echo
Description: Imaging of muscles applying Multi-spectral optoacoustic tomography (MSOT)

Intervention type: DEVICE
Group type: OTHER
Intervention: MSOT Acuity Echo
Description: Imaging of muscles applying Multi-spectral optoacoustic tomography (MSOT)
Study: NCT05446701

Intervention type: DIAGNOSTIC_TEST
Intervention: serum level of FAM19A5
Description: Detection of serum level of FAM19A5 of patients and controls by using ELISA technique.

Intervention type: DIAGNOSTIC_TEST
Intervention: serum level of FAM19A5
Description: Detection of serum level of FAM19A5 of patients and controls by using ELISA technique.
Study: NCT05453227

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zinc
Description: To test the effect of a novel zinc-containing vaginal topical on GSM/VVA symptoms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc
Description: To test the effect of a novel zinc-containing vaginal topical on GSM/VVA symptoms.
Study: NCT04911777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentarlandir™ UPPTA
Description: Pentarlandir™ UPPTA is a white oral capsule (with 188 mg of UPPTA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentarlandir™ UPPTA
Description: Pentarlandir™ UPPTA is a white oral capsule (with 188 mg of UPPTA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo of Pentarlandir™ UPPTA is a white oral capsule (without UPPTA)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo of Pentarlandir™ UPPTA is a white oral capsule (without UPPTA)
Study: NCT06128330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid bolus 20 mg/kg
Description: Bolus of tranexamic acid in the standard dose group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid bolus 10 mg/kg
Description: Bolus of tranexamic acid in the low dose group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid bolus 1 mg/kg
Description: Bolus of tranexamic acid in the low dose group (to add into the CPB prime)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid continuous infusion of 1 mg/kg/h in the low dose group
Description: Tranexamic acid continuous infusion during the procedure
Study: NCT04524533

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental smoking cessation video
Description: Participants who are randomized to the intervention group will watch an educational video that includes tips on quitting smoking during a dental cleaning. The video is approximately 10 minutes long and tailored to readiness to quit at the time of the dental visit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control video
Description: Participants randomized to the control group will watch a 10 minute video.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brochure of smoking cessation EBTs
Description: All participants will receive identical print materials on EBTs consistent with smoking cessation standard clinical care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brochure of smoking cessation EBTs
Description: All participants will receive identical print materials on EBTs consistent with smoking cessation standard clinical care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored text message program
Description: Participants randomized to the intervention group will be enrolled in a 4-week tailored text message program which includes assessment questions in addition to text messages geared towards motivating and facilitating EBT utilization for individuals ready to quit smoking and individuals who are not ready to quit smoking.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment text messages
Description: Participants randomized to the control group will be enrolled in a different 4-week text message program that includes only assessment questions.
Study: NCT05524987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ANDES INTERVENTION
Description: ANDES intervention group will receive the ANDES implementation package consisting of health agent home visits for 12 consecutive months
Study: NCT06480448

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical herapy
Description: core stability, strengthening exercises, stationary bicycle training and sustained strechinng exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training
Description: Treadmill training for 20 minutes three time a week.
Study: NCT06162403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Stimulation
Description: The leads are inserted through a needle. If needed, the study team may give participants anesthetic (for example, as a cream/gel on your skin and/or as an injection) to numb the area where the leads will be injected.
Study: NCT06073795

Intervention type: PROCEDURE
Intervention: sympathetic block
Description: LSGBs will be performed at the lower third of the L2 or the upper third of the L3 vertebra without any premedication. The targeted lumbar vertebra will be identified with an anteroposterior (AP) fluoroscopic imaging in the FL group or with an US longitudinal tracing approach from the caudad to cephalad direction in the US group. The skin entry point will be infiltrated with 1% lidocaine. Then, a curved 21 G, 15-cm Chiba needle will be advanced toward the target using the posterolateral approach in both groups. Each patient will undergo LSGBs according to the allocated group.

Intervention type: PROCEDURE
Intervention: sympathetic block
Description: LSGBs will be performed at the lower third of the L2 or the upper third of the L3 vertebra without any premedication. The targeted lumbar vertebra will be identified with an anteroposterior (AP) fluoroscopic imaging in the FL group or with an US longitudinal tracing approach from the caudad to cephalad direction in the US group. The skin entry point will be infiltrated with 1% lidocaine. Then, a curved 21 G, 15-cm Chiba needle will be advanced toward the target using the posterolateral approach in both groups. Each patient will undergo LSGBs according to the allocated group.
Study: NCT04372498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Senicapoc (synonyms: ICA-17043; 2,2-bis-(4-fluorophenyl)-2-phenylacetamide)
Description: This study is conducted as open label, with each patient's response determined with an adaptive Bayesian model based on historical and baseline values for the primary endpoints of the trial. 3 monthly dose escalation steps will assess the efficacy of senicapoc in a dose range (10-40 mg/day) which has been used in prior trials for other indications.
Study: NCT05821712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.2% zinc lactate, 0.17% amine fluoride and 0.0275% sodium fluoride Mouthwash
Description: mouthwash

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.057% sodium fluoride Mouthwash
Description: mouthwash
Study: NCT04740710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing and Attention Training
Description: A guided audio recording will instruct participants to alter their breathing and pay attention in specific ways.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breathing and Attention Training
Description: A guided audio recording will instruct participants to alter their breathing and pay attention in specific ways.